Friedreich’s ataxia: major trial readouts and regulatory events to watch in 2023
The FDA could approve the first treatment for Friedreich’s ataxia, and at least three other major trials have readouts expected by year end.
Features
Is the healthcare industry spearheading the metaverse?
Boon and bane: dodging participant burden in decentralised clinical trials
Pipeline Moves: Novartis resumes Phase II myelofibrosis trial, oncology trial completions
Running low on comparators: navigating drug shortages in oncology clinical trials
ACT EU state of play: EMA’s headway to transform clinical trials
Pipeline Moves: approval prospects jump for AstraZeneca’s breast cancer drug
Blockchain in clinical trial supply chains: more hype than heft?
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
